NASDAQ: SCPHScpharmaceuticals Inc Stock
$4.56+0.05 (+1.11%)
Updated Apr 19, 2024
SCPH Price
$4.56
Fair Value Price
$3.30
Market Cap
$164.41M
52 Week Low
$4.25
52 Week High
$12.75
P/E
-3.21x
P/B
4.42x
P/S
17.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.59M
Earnings
-$54.81M
Gross Margin
72%
Operating Margin
-343.46%
Profit Margin
-403.2%
Debt to Equity
1.54
Operating Cash Flow
-$59M
Beta
1.01
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SCPH Overview
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SCPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCPH ($4.56) is overvalued by 38.07% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SCPH ($4.56) is not significantly undervalued (38.07%) relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SCPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SCPH due diligence checks available for Premium users.
Be the first to know about important SCPH news, forecast changes, insider trades & much more!
SCPH News
Valuation
SCPH fair value
Fair Value of SCPH stock based on Discounted Cash Flow (DCF)
Price
$4.56
Fair Value
$3.30
Overvalued by
38.07%
SCPH ($4.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SCPH ($4.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SCPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SCPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.21x
Industry
15.81x
Market
40.51x
SCPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.42x
Industry
5.74x
SCPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCPH's financial health
Profit margin
Revenue
$6.1M
Net Income
-$13.8M
Profit Margin
-226.6%
SCPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$94.5M
Liabilities
$57.3M
Debt to equity
1.54
SCPH's short-term assets ($92.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCPH's short-term assets ($92.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.2M
Investing
$26.5M
Financing
$467.0k
SCPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCPH vs Biotech Stocks
Scpharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.